{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["5(7)"],"submitter":["O'Brien TJ"],"pubmed_abstract":["<h4>Importance</h4>Cannabidiol has shown efficacy in randomized clinical trials for drug-resistant epilepsy in specific syndromes that predominantly affect children. However, high-level evidence for the efficacy and safety of cannabidiol in the most common form of drug-resistant epilepsy in adults, focal epilepsy, is lacking.<h4>Objective</h4>To investigate the efficacy, safety, and tolerability of transdermally administered cannabidiol in adults with drug-resistant focal epilepsy.<h4>Design, setting, and participants</h4>A randomized, double-blind, placebo-controlled, multicenter clinical trial at 14 epilepsy trial centers in Australia and New Zealand. Participants were adults with drug-resistant focal epilepsy receiving a stable regimen of up to 3 antiseizure medications. Data were analy"],"journal":["JAMA network open"],"pagination":["e2220189"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9270696"],"repository":["biostudies-literature"],"pubmed_title":["Adjunctive Transdermal Cannabidiol for Adults With Focal Epilepsy: A Randomized Clinical Trial."],"pmcid":["PMC9270696"],"pubmed_authors":["D'Souza W","Sebree TB","Rosemergy I","Bergin P","Frasca J","Anderson T","Reutens D","Nikpour A","Seneviratne U","Messenheimer JA","Gutterman DL","French JA","O'Brien TJ","Wijayath M","STAR 1/STAR 2 Study Group","Bonn-Miller MO","Patrikios P","Berkovic SF","Kwan P","Asztely F"],"additional_accession":[]},"is_claimable":false,"name":"Adjunctive Transdermal Cannabidiol for Adults With Focal Epilepsy: A Randomized Clinical Trial.","description":"<h4>Importance</h4>Cannabidiol has shown efficacy in randomized clinical trials for drug-resistant epilepsy in specific syndromes that predominantly affect children. However, high-level evidence for the efficacy and safety of cannabidiol in the most common form of drug-resistant epilepsy in adults, focal epilepsy, is lacking.<h4>Objective</h4>To investigate the efficacy, safety, and tolerability of transdermally administered cannabidiol in adults with drug-resistant focal epilepsy.<h4>Design, setting, and participants</h4>A randomized, double-blind, placebo-controlled, multicenter clinical trial at 14 epilepsy trial centers in Australia and New Zealand. Participants were adults with drug-resistant focal epilepsy receiving a stable regimen of up to 3 antiseizure medications. Data were analy","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2025-04-27T00:06:45.964Z","creation":"2025-02-18T22:39:58.974Z"},"accession":"S-EPMC9270696","cross_references":{"pubmed":["35802375"],"doi":["10.1001/jamanetworkopen.2022.20189"]}}